Actively Recruiting
National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-06-17
9999
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a large-scale, long-term study on hematological diseases, focusing on large granular lymphocytic leukemia (LGLL), a disorder affecting blood and blood-forming organs. This study aims to better understand the incidence, risk factors, treatment effectiveness, patient outcomes, and healthcare costs related to LGLL in China, addressing gaps from previous smaller or limited studies. The study combines retrospective and prospective observational methods. It collects detailed patient information from medical records, including diagnosis, treatment, and health costs. Patients diagnosed with LGLL from January 1, 2000, onward at participating hospitals are included. Questionnaires assess patient exposure, and ongoing follow-up gathers prognosis and health-related quality of life data. Participants will have their hematologic response evaluated at the start, and then at 6, 12, and 24 months after treatment, with additional assessments at study completion. Researchers will examine clinical features, treatment patterns, relapses, mortality, and long-term outcomes. The study involves continuous monitoring over many years to provide comprehensive insights into LGLL progression and management.
CONDITIONS
Brief Title
National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with large granular lymphocytic leukemia (LGLL).
- Treated at the Institute of Hematology and Blood Diseases Hospital from January 1, 2000 onward.
You will not qualify if you...
- Unlikely to be available for long-term follow-up for any reason, including severe health problems.
- Alcohol or drug dependence that may reduce compliance with the study.
- Other reasons determined by the investigator that make participation unsuitable.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 months
Participants diagnosed with large granular lymphocytic leukemia are observed through collection of medical records, questionnaires, and prognosis information.
Visits at baseline, 6 months, 12 months, and 24 months
Trial Site Locations
Total: 1 location
1
Red Blood Cell Diseases Center and Regenerative Medicine Center
Tianjin, Tianjin Municipality, China, 301617
Actively Recruiting
Research Team
L
Lele Zhang, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here